Security Investigation
AstraZeneca PLC (NasdaqGS: AZN)
54 Days left to seek lead plaintiff status.
Contact a Lawyer Now
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 21, 2025 to file lead plaintiff applications in a securities class action lawsuit against AstraZeneca PLC (the “Company”) (NasdaqGS: AZN).
AstraZeneca and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (1) the Company engaged in insurance fraud in China; (2) as a result, the Company faced heightened legal exposure in China, which eventually resulted in the AstraZeneca China President being detained by Chinese law enforcement authorities; (3) as a result, the Company understated its legal risks; (4) the foregoing, once revealed, could materially harm the Company’s business activities in China; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you purchased securities of AstraZeneca and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or fill out the form on this page.
The case is Saleh v. AstraZeneca PLC, et al., No. 24-cv-11021.